Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An international multi-centre trial of tamoxifen versus anastrozole in postmenopausal women who have had a recent hormone receptor positive, Ductal Carcinoma In Situ (DCIS)

Trial Profile

An international multi-centre trial of tamoxifen versus anastrozole in postmenopausal women who have had a recent hormone receptor positive, Ductal Carcinoma In Situ (DCIS)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Nov 2018

At a glance

  • Drugs Anastrozole (Primary) ; Risedronic acid; Tamoxifen
  • Indications Early breast cancer; Osteoporosis
  • Focus Therapeutic Use
  • Acronyms ANZ 02P2; IBIS-II; IBIS-II-DCIS
  • Most Recent Events

    • 16 Nov 2018 This trial has been completed in Sweden.
    • 31 Aug 2018 Biomarkers information updated
    • 07 Oct 2013 Results of an analysis of the bone substudy (n=289) presented at the 35th Annual Meeting of the American Society for Bone and Mineral Research.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top